- Home
- AMPL vs VRDN Comparison
AMPL vs VRDN Comparison
Compare AMPL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMPL | VRDN |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.1B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMPL | VRDN |
|---|---|---|
| Price | $13.38 | $22.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $13.42 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,214,000.00 | $5,706,000.00 |
| Revenue This Year | $17.43 | $13.73 |
| Revenue Next Year | $14.16 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $13.18 |
| 52 Week High | $14.76 | $34.29 |
Technical Indicators
Market Signals| Indicator | AMPL | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 48.05 |
| Support Level | $6.05 | $21.40 |
| Resistance Level | $13.58 | $23.84 |
| Average True Range (ATR) | 0.59 | 0.87 |
| MACD | -0.10 | -0.23 |
| Stochastic Oscillator | 60.84 | 35.85 |
Price Performance
Historical ComparisonAbout AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.